{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:32:21Z","timestamp":1792099941658,"version":"4.4.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s13555-021-00648-z","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T17:21:10Z","timestamp":1638292870000},"page":"149-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8851-350X","authenticated-orcid":false,"given":"Kathleen W.","family":"Wyrwich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1617-967X","authenticated-orcid":false,"given":"Randall","family":"Winnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5565-4712","authenticated-orcid":false,"given":"Randall","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-2467","authenticated-orcid":false,"given":"Kavita","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1631-929X","authenticated-orcid":false,"given":"Nimanee","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7117-6757","authenticated-orcid":false,"given":"Lauren","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"648_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2147\/CCID.S245649","volume":"13","author":"M Benigno","year":"2020","unstructured":"Benigno M, Anastassopoulos KP, Mostaghimi A, Udall M, Daniel SR, Cappelleri JC, et al. A large cross-sectional survey study of the prevalence of alopecia areata in the United States. Clin Cosmet Investig Dermatol. 2020;13:259\u201366.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"6","key":"648_CR2","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/0190-9622(92)70134-2","volume":"26","author":"TF Cash","year":"1992","unstructured":"Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol. 1992;26(6):926\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"648_CR3","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/0190-9622(93)70223-G","volume":"29","author":"TF Cash","year":"1993","unstructured":"Cash TF, Price VH, Savin RC. Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol. 1993;29(4):568\u201375.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"648_CR4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1046\/j.1365-4362.2003.01340.x","volume":"42","author":"S Ruiz-Doblado","year":"2003","unstructured":"Ruiz-Doblado S, Carrizosa A, Garcia-Hernandez MJ. Alopecia areata: psychiatric comorbidity and adjustment to illness. Int J Dermatol. 2003;42(6):434\u20137.","journal-title":"Int J Dermatol"},{"key":"648_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pharmthera.2017.05.008","volume":"179","author":"G Skogberg","year":"2017","unstructured":"Skogberg G, Jackson S, Astrand A. Mechanisms of tolerance and potential therapeutic interventions in Alopecia Areata. Pharmacol Ther. 2017;179:102\u201310.","journal-title":"Pharmacol Ther"},{"key":"648_CR6","unstructured":"Food and Drug Administration (FDA). Patient-focused drug development: methods to identify what is important to patients. Draft guidance for industry, Food and Drug Administration staff, and other stakeholders. 2019. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients-guidance-industry-food-and. Accessed 2 Aug 2020."},{"issue":"4 (suppl 1)","key":"648_CR7","first-page":"AB46","volume":"81","author":"R Winnette","year":"2019","unstructured":"Winnette R, Martin S, Harris N, Deal L. Development of the alopecia areata patient priority outcomes instrument, a new patient reported outcome measure. J Am Acad Dermatol. 2019;81(4 (suppl 1)):AB46.","journal-title":"J Am Acad Dermatol"},{"key":"648_CR8","unstructured":"Food and Drug Administration (FDA). Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf. Accessed 29 Mar 2020."},{"issue":"3","key":"648_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"EA Olsen","year":"2004","unstructured":"Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines\u2014part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"648_CR10","volume-title":"Totalis alopecia","author":"J Buckley","year":"2020","unstructured":"Buckley J, Rapini RP. Totalis alopecia. Treasure Island: StatPearls; 2020."},{"issue":"4","key":"648_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/jdv.15994","volume":"34","author":"B Burroway","year":"2020","unstructured":"Burroway B, Griggs J, Tosti A. Alopecia totalis and universalis long-term outcomes: a review. J Eur Acad Dermatol Venereol. 2020;34(4):709\u201315.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"648_CR12","unstructured":"National Alopecia Areata Foundation. What you need to know about the different types of alopecia areata. 2021. https:\/\/www.naaf.org\/alopecia-areata\/types-of-alopecia-areata. Accessed 3 Feb 2021."},{"issue":"2 Pt 1","key":"648_CR13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0190-9622(99)70195-7","volume":"40","author":"E Olsen","year":"1999","unstructured":"Olsen E, Hordinsky M, McDonald-Hull S, Price V, Roberts J, Shapiro J, et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol. 1999;40(2 Pt 1):242\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"648_CR14","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jisp.2017.10.009","volume":"19","author":"TR Mendoza","year":"2018","unstructured":"Mendoza TR, Osei J, Duvic M. The utility and validity of the alopecia areata symptom impact scale in measuring disease-related symptoms and their effect on functioning. J Investig Dermatol Symp Proc. 2018;19(1):S41\u20136.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"648_CR15","volume-title":"How to score the revised MOS short-form health scales","author":"JEJ Ware","year":"1988","unstructured":"Ware JEJ. How to score the revised MOS short-form health scales. Boston: Institute for the Improvement of Medical Care and Health; 1988."},{"key":"648_CR16","volume-title":"User\u2019s manual for the SF-36v2 Health Survey","author":"MEE Maruish","year":"2011","unstructured":"Maruish MEE. User\u2019s manual for the SF-36v2 Health Survey. 3rd ed. Lincoln: QualityMetric Incorporated; 2011.","edition":"3"},{"key":"648_CR17","unstructured":"SAS Institute I. SAS proprietary software, version 9.4. Cary (NC); 2012."},{"key":"648_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/PROM.S145676","volume":"9","author":"K Dean","year":"2018","unstructured":"Dean K, Walker Z, Jenkinson C. Data quality, floor and ceiling effects, and test-retest reliability of the Mild Cognitive Impairment Questionnaire. Patient Relat Outcome Meas. 2018;9:43\u20137.","journal-title":"Patient Relat Outcome Meas"},{"key":"648_CR19","volume-title":"Mplus user\u2019s guide","author":"LK Muth\u00e9n","year":"2015","unstructured":"Muth\u00e9n LK, Muth\u00e9n BO. Mplus user\u2019s guide. 7th ed. Los Angeles: Muth\u00e9n & Muth\u00e9n; 1998-2015.","edition":"7"},{"key":"648_CR20","volume-title":"Testing structural equation models","author":"MW Browne","year":"1993","unstructured":"Browne MW, Cudeck R. Alternative ways of assessing model fit. In: Bollen KA, Long JS, editors. Testing structural equation models. Newbury Park: Sage; 1993."},{"issue":"2","key":"648_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1207\/s15327906mbr2502_4","volume":"25","author":"JH Steiger","year":"1990","unstructured":"Steiger JH. Structural model evaluation and modification: an interval estimation approach. Multivar Behav Res. 1990;25(2):173\u201380.","journal-title":"Multivar Behav Res"},{"key":"648_CR22","volume-title":"EQS structural equations program manual","author":"PM Bentler","year":"1989","unstructured":"Bentler PM. EQS structural equations program manual. Los Angeles: BMDP Statistical Software; 1989."},{"issue":"1","key":"648_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02291170","volume":"38","author":"LR Tucker","year":"1973","unstructured":"Tucker LR, Lewis C. A reliability coefficient for maximum likelihood factor analysis. Psychometrika. 1973;38(1):1\u201310.","journal-title":"Psychometrika"},{"issue":"1","key":"648_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10705519909540118","volume":"6","author":"L Hu","year":"1999","unstructured":"Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model. 1999;6(1):1\u201355.","journal-title":"Struct Equ Model"},{"key":"648_CR25","volume-title":"A beginner\u2019s guide to structural equation modeling","author":"RE Schumacker","year":"1996","unstructured":"Schumacker RE, Lomax RG. A beginner\u2019s guide to structural equation modeling. Mahwah: Erlbaum; 1996."},{"key":"648_CR26","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/001316447303300309","volume":"33","author":"JL Fleiss","year":"1973","unstructured":"Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas. 1973;33:613\u20139.","journal-title":"Educ Psychol Meas"},{"key":"648_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199685219.001.0001","volume-title":"Health Measurement Scales: a practical guide to their development and use","author":"DL Streiner","year":"2015","unstructured":"Streiner DL, Norman GR, Cairney J. Health Measurement Scales: a practical guide to their development and use. 5th ed. Oxford: Oxford University Press; 2015.","edition":"5"},{"issue":"2","key":"648_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11336-012-9258-4","volume":"77","author":"M Warrens","year":"2012","unstructured":"Warrens M. Some paradoxical results for the quadratically weighted kappa. Psychometrika. 2012;77(2):315\u201323.","journal-title":"Psychometrika"},{"key":"648_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1037\/1082-989X.1.1.30","volume":"1","author":"KO McGraw","year":"1996","unstructured":"McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1:30\u201346.","journal-title":"Psychol Methods"},{"key":"648_CR30","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","volume":"86","author":"PE Shrout","year":"1979","unstructured":"Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420\u20138.","journal-title":"Psychol Bull"},{"issue":"1","key":"648_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159\u201374.","journal-title":"Biometrics"},{"key":"648_CR32","volume-title":"Psychometric theory","author":"JC Nunnally","year":"1994","unstructured":"Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994.","edition":"3"},{"key":"648_CR33","unstructured":"Food and Drug Administration (FDA). Methods to identify what is important to patients and select, develop or modify fit-for-purpose clinical outcomes assessments. Patient-focused drug development guidance public workshop. October 15\u201316 2018. https:\/\/www.fda.gov\/media\/116281\/download. Accessed 4 Feb 2020."},{"key":"648_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/BF02310555","volume":"16","author":"L Cronbach","year":"1951","unstructured":"Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297\u2013334.","journal-title":"Psychometrika"},{"key":"648_CR35","doi-asserted-by":"publisher","DOI":"10.1201\/b16139","volume-title":"Patient-reported outcomes: measurement, implementation and interpretation","author":"JC Cappelleri","year":"2013","unstructured":"Cappelleri JC, Zou KH, Bushmakin AG, Alvir JM, Alemayehu D, Symonds T. Patient-reported outcomes: measurement, implementation and interpretation. Cambridge: CRC Press; 2013."},{"key":"648_CR36","volume-title":"HIS: RAND-36 health status inventory","author":"R Hays","year":"1998","unstructured":"Hays R, Prince-Embury S, Chen H. HIS: RAND-36 health status inventory. San Antonio: The Psychological Corporation; 1998."},{"issue":"1","key":"648_CR37","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J. A power primer. Psychol Bull. 1992;112(1):155\u20139.","journal-title":"Psychol Bull"},{"issue":"4","key":"648_CR38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1067\/mjd.2000.103909","volume":"42","author":"S Madani","year":"2000","unstructured":"Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000;42(4):549\u201366.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"648_CR39","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/bjd.19024","volume":"183","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, et al. Development of the Scalp Hair Assessment PRO measure for alopecia areata. Br J Dermatol. 2020;183(6):1065\u201372.","journal-title":"Br J Dermatol"},{"issue":"1","key":"648_CR40","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1016\/j.jisp.2020.05.007","volume":"20","author":"N Mesinkovska","year":"2020","unstructured":"Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in Alopecia Areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20(1):S62\u20138.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"5","key":"648_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1023\/A:1012552211996","volume":"10","author":"C Taft","year":"2001","unstructured":"Taft C, Karlsson J, Sullivan M. Do SF-36 summary component scores accurately summarize subscale scores? Qual Life Res. 2001;10(5):395\u2013404.","journal-title":"Qual Life Res"},{"issue":"19","key":"648_CR42","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.2106\/JBJS.O.00030","volume":"97","author":"NC Laucis","year":"2015","unstructured":"Laucis NC, Hays RD, Bhattacharyya T. Scoring the SF-36 in orthopaedics: a brief guide. J Bone Jt Surg Am. 2015;97(19):1628\u201334.","journal-title":"J Bone Jt Surg Am"},{"issue":"3","key":"648_CR43","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1111\/j.1468-3083.2012.04629.x","volume":"27","author":"G Fabbrocini","year":"2013","unstructured":"Fabbrocini G, Panariello L, De Vita V, Vincenzi C, Lauro C, Nappo D, et al. Quality of life in alopecia areata: a disease-specific questionnaire. J Eur Acad Dermatol Venereol. 2013;27(3):e276\u201381.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"648_CR44","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1684\/ejd.2012.1752","volume":"22","author":"Y Endo","year":"2012","unstructured":"Endo Y, Miyachi Y, Arakawa A. Development of a disease-specific instrument to measure quality of life in patients with alopecia areata. Eur J Dermatol. 2012;22(4):531\u20136.","journal-title":"Eur J Dermatol"},{"issue":"8","key":"648_CR45","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/jdv.17370","volume":"35","author":"PV Chernyshov","year":"2021","unstructured":"Chernyshov PV, Tomas-Aragones L, Finlay AY, Manolache L, Marron SE, Sampogna F, et al. Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. J Eur Acad Dermatol Venereol. 2021;35(8):1614\u201321.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"648_CR46","unstructured":"ClinicalTrials.gov. NCT3732807: PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b\/3). 2020. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03732807. Accessed 3 Feb 2021."},{"key":"648_CR47","unstructured":"ClinicalTrials.gov. NCT04006457: long-term PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-LT). 2020. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04006457. Accessed 3 Feb 2021."}],"updated-by":[{"DOI":"10.1007\/s13555-022-00718-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T00:00:00Z","timestamp":1649548800000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00648-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-021-00648-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00648-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T18:03:17Z","timestamp":1649613797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-021-00648-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["648"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00648-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13555-022-00718-w","asserted-by":"object"}]},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]},"assertion":[{"value":"28 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13555-022-00718-w","URL":"https:\/\/doi.org\/10.1007\/s13555-022-00718-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}